BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites - 2Impact of NIH funding reductions felt in cancer and infectious disease trials
- 3Which Breakfast Enraptures Your Taste Buds? Vote
- 4Which Carrier Do You Suggest? Vote
- 5Reviving Your Home with Nutritious Indoor Plants
- Architect Frank Gehry has died: See his most iconic buildings
- Vote In favor of Your Number one Savvy Beds
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Which Brilliant Home Gadget Can't You Reside Without?
- Von der Leyen: Paris meeting sends signal of unity for Ukraine
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- How 2025 became the year of comet: The rise of interstellar 3I/ATLAS, an icy Lemmon and a cosmic SWAN
- High velocity Internet services for Metropolitan Regions
- Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
